Pfizer, EMD Serono to scrap phase 3 study of avelumab in LA SCCHN

This article was originally published here

The later stage trial has been evaluating avelumab plus chemoradiotherapy (CRT) in comparison to standard-of-care CRT in patients having untreated locally advanced squamous cell carcinoma of the head

The post Pfizer, EMD Serono to scrap phase 3 study of avelumab in LA SCCHN appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply